It is a new week, and stocks are back in the interest of the public after recent gains. Now investors have to decide which stocks are still buys, while also determining which stocks should be sold or avoided. Each morning 24/7 Wall St. reviews dozens of Wall Street analyst research reports with the prime goal of finding fresh ideas for investors and traders. Some of the calls turn out to be new stocks to buy and some turn out to be stocks to sell. These are this Monday’s top analyst upgrades, downgrades and initiations seen from Wall Street research firms.
Apache Corp. (NYSE: APA) was reiterated as Buy and the price target was raised to $104 from $100, based on a higher net asset value, at Credit Suisse.
Arcos Dorados Holdings Inc. (NYSE: ARCO) was started as Neutral at Credit Suisse.
Blackstone Group L.P. (NYSE: BX) was raised to Buy from Neutral at BofA/Merrill Lynch.
Boeing Co. (NYSE: BA) was reiterated as Buy and saw its price target raised to a street high of $164 from $120 by Sterne Agee.
Huntsman Corp. (NYSE: HUN) was raised to Buy from Hold at Jefferies.
MedAssets Inc. (NASDAQ: MDAS) was reiterated as Buy by Sterne Agee, but it raised the price target to $30 for its top pick within health care.
Regado Biosciences Inc. (NASDAQ: RGDO) was started as Buy but was given a $14 price target by Canaccord Genuity. The firm said that its controllable anticoagulation comes of age, but that $14 target is some 200% higher than the $4.60 close of this small $93 million biotech.
Telecom Italia SPA (NYSE: TI) was downgraded to Sell from Neutral at Citigroup.
Under Armour Inc. (NYSE: UA) was downgraded to Neutral from Positive at Susquehanna.
Western Union (NYSE: WU) was raised to Buy from Neutral at Sterne Agee.
Barclays has made changes on European drug makers: it upgraded Sanofi (NYSE: SNY) to Overweight from Equal Weight, while it downgraded GlaxoSmithKline PLC (NYSE: GSK) from Overweight to Equal Weight.
Citigroup has raised its 2014 stock market price targets: S&P 500 to 1,900 and DJIA to 17,100.
Wall Street sees two distinct areas and several key companies making the next wave of tens of billions of dollars from drug and biotech.